Legal Updates, Stock Price Movements, New Awareness Campaigns, and Senior-level Appointments - Analyst Notes on Mylan, WellPoint, Forest, Novatis and Intercept

NEW YORK, April 15, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Mylan Inc. (NASDAQ: MYL), WellPoint Inc. (NYSE: WLP), Forest Laboratories Inc. (NYSE: FRX), Novatis AG (NYSE: NVS) and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1162-100free.

--
Mylan Inc. Analyst Notes
On April 11, 2014, Mylan Inc. (Mylan) announced that a federal district court has accepted its request to enforce a settlement agreement between Endo Pharmaceuticals (Endo) and Mylan settling patent litigation in connection with Mylan's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Frovatriptan Succinate Tablets, 2.5 mg. According to the Company, Frovatriptan Succinate is the generic version of FROVA®, which is used to treat acute migraine headaches in adults. As a result of this decision, the court has overturned its earlier decision, which was in favor of Endo, and would have stopped Mylan from launching the product until the U.S. Patent 5,464,864 patent on November 7, 2015 was exhausted. With this settlement, Mylan can now launch FROVA® depending upon FDA approval. The full analyst notes on Mylan are available to download free of charge at:

http://www.analystsreview.com/1162-MYL-.pdf

--
WellPoint Inc. Analyst Notes
On April 10, 2014, shares of WellPoint Inc. (WellPoint) declined 1.11% to end the day at $95.74, tracking losses in the S&P 500 Index, which declined 2.09%. WellPoint's stock opened the session at $97.01 and oscillated in the range of $95.12 - $97.74. The stock touched its 52-week high of $102.56 on March 21, 2014 - the day the Company held its Investor Day. On its Investor Day, the Company raised its 2014 earnings forecast to more than $8.20 per share from more than $8.00, after saying it had expanded its customer base through Obamacare. Over the past three months, the stock has gained 4.08% outperforming the S&P 500 Index that lost 0.50% over the same period. WellPoint is the biggest commercial insurer in the Obamacare exchanges with 500,000 members through January 2014. The full analyst notes on WellPoint are available to download free of charge at:

http://www.analystsreview.com/1162-WLP-.pdf

--
Forest Laboratories Inc. Analyst Notes
On April 10, 2014, Forest Laboratories Inc. (Forest) and Ironwood Pharmaceuticals Inc. (Ironwood) announced the commencement of a new direct-to-consumer (DTC) patient awareness campaign for LINZESS® (linaclotide), a treatment for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). According to the Company, the campaign helps adults with IBS-C or CIC, recognize the symptoms of these disorders, describe their symptoms to their doctor, and ask their doctor about LINZESS to help proactively manage their disease. LINZESS is the first and only FDA-approved treatment used as a new class of medicines for IBS-C and CIC known as GC-C agonists. Bill Meury, Executive Vice President, Sales and Marketing, Forest said, "Forest has traditionally focused primarily on physician-facing activities rather than DTC, but with LINZESS, we felt we had a unique opportunity to reach patients who were having a difficult time identifying and conveying the symptoms they were experiencing." The full analyst notes on Forest are available to download free of charge at:

http://www.analystsreview.com/1162-FRX-.pdf

--
Novatis AG Analyst Notes
On April 9, 2014, Novatis AG (Novartis) announced the appointment of Jeff George as the Head of Alcon Division, with effect from May 1, 2014. George will succeed Kevin Buehler who is retiring from the Company. George will continue to serve as a member of the Executive Committee of Novartis, reporting to Joseph Jimenez, CEO, Novartis. In addition, the Company has appointed Richard Francis as the Head of the Sandoz Division. Francis was previously working with Biogen Idec as Senior Vice President, U.S. Commercial Operations. Further, Francis will also be inducted into the Executive Committee of Novartis. Commenting on the appointments, Jimenez said, "The appointments of Jeff George as the new Division Head of Alcon, and of Richard Francis as new Division Head of Sandoz place two strong leaders at the helm of two leading Novartis businesses." The full analyst notes on Novatis are available to download free of charge at:

http://www.analystsreview.com/1162-NVS-.pdf

--
Intercept Pharmaceuticals Inc. Analyst Notes
On April 10, 2014, shares in Intercept Pharmaceuticals Inc. (Intercept) slipped 11.64% to end the trading session at $264.68, following the NASDAQ Composite, which lost 3.10%, due to heavy sell-off in technology stocks, amid concerns that the valuations may be too high at the start of the earnings season. Intercept's stock opened the session at $302.04 and fluctuated between $256.00 and $305.95. Over the past six months, the stock has gained 340.99% outperforming the NASDAQ Composite which returned 6.92% over the same period. However, in the past one month, the stock has declined 39.59%, after adverse comments on its FLINT trial. The full analyst notes on Intercept are available to download free of charge at:

http://www.analystsreview.com/1162-ICPT-.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review